Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease
Autor: | Vincent J Colucci, Judy W.M. Cheng, Sarah A Spinler, James S. Kalus |
---|---|
Rok vydání: | 2020 |
Předmět: |
Heart Failure
medicine.medical_specialty business.industry Disease Type 2 diabetes 030204 cardiovascular system & hematology medicine.disease Clinical trial 03 medical and health sciences 0302 clinical medicine Diabetes Mellitus Type 2 Sodium-Glucose Transporter 2 Chronic Kidney Diseases Heart failure Internal medicine Diabetes mellitus Humans Medicine Pharmacology (medical) In patient 030212 general & internal medicine Renal Insufficiency Chronic business Sodium-Glucose Transporter 2 Inhibitors Kidney disease |
Zdroj: | Annals of Pharmacotherapy. 55:252-260 |
ISSN: | 1542-6270 1060-0280 |
Popis: | Sodium-glucose cotransporter (SGLT2) inhibitors have demonstrated cardiovascular (CV) benefits in large-scale clinical trials of people who have type 2 diabetes and either established CV disease or multiple CV risk factors. These studies also indicated early signals in benefiting heart failure (HF) patients and those with chronic kidney diseases. This article reviews recent and future clinical studies that focus on evaluation of the use of SGLT2 inhibitors in HF management and renal protection. |
Databáze: | OpenAIRE |
Externí odkaz: |